help button home button
AJRCCM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by AOSHIBA, K.
Right arrow Articles by NAGAI, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by AOSHIBA, K.
Right arrow Articles by NAGAI, A.

Am. J. Respir. Crit. Care Med., Volume 162, Number 2, August 2000, 695-700

The Fas/Fas-Ligand System Is Not Required for Bleomycin-induced Pulmonary Fibrosis in Mice

KAZUTETSU AOSHIBA, SHUJI YASUI, JUN TAMAOKI, and ATSUSHI NAGAI

First Department of Medicine, Tokyo Women's Medical University, Tokyo, Japan

Recent studies suggest that Fas-Fas-ligand (FasL) interactions play an important role in the development of lung injury and fibrosis. However, evidence to support this concept is still indirect. To determine whether Fas-FasL interaction is required for the development of bleomycin-induced pulmonary fibrosis in mice, we used Fas-deficient (lpr) and FasL-deficient (gld ) mice as animal models. After intratracheal instillation of bleomycin, we examined the lungs of mice through bronchoalveolar lavage, histologic studies, DNA nick-end labeling, and hydroxyproline assay. The development of cellular infiltrates, bronchiolar and alveolar epithelial apoptosis, and fibrosis following bleomycin instillation in the lungs in lpr mice and gld mice was similar to their development in wild-type mice. The results of this study show that bleomycin-induced pulmonary fibrosis does not require Fas-FasL interaction, and that epithelial cell apoptosis after bleomycin exposure is mediated by Fas-independent pathways.




This article has been cited by other articles:


Home page
 Am. J. Physiol. Lung Cell. Mol. Physiol.Home page
S. B. Wallach-Dayan, G. Izbicki, P. Y. Cohen, R. Gerstl-Golan, A. Fine, and R. Breuer
Bleomycin initiates apoptosis of lung epithelial cells by ROS but not by Fas/FasL pathway
Am J Physiol Lung Cell Mol Physiol, April 1, 2006; 290(4): L790 - L796.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
G. R. S. Budinger, G. M. Mutlu, J. Eisenbart, A. C. Fuller, A. A. Bellmeyer, C. M. Baker, M. Wilson, K. Ridge, T. A. Barrett, V. Y. Lee, et al.
Proapoptotic Bid is required for pulmonary fibrosis
PNAS, March 21, 2006; 103(12): 4604 - 4609.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Lung Cell. Mol. Physiol.Home page
V. Y. Lee, C. Schroedl, J. K. Brunelle, L. J. Buccellato, O. I. Akinci, H. Kaneto, C. Snyder, J. Eisenbart, G. R. S. Budinger, and N. S. Chandel
Bleomycin induces alveolar epithelial cell death through JNK-dependent activation of the mitochondrial death pathway
Am J Physiol Lung Cell Mol Physiol, October 1, 2005; 289(4): L521 - L528.
[Abstract] [Full Text] [PDF]

Home page
 J. Appl. Physiol.Home page
X. Li, R. Shu, G. Filippatos, and B. D. Uhal
Apoptosis in lung injury and remodeling
J Appl Physiol, October 1, 2004; 97(4): 1535 - 1542.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
N. Yokohori, K. Aoshiba, and A. Nagai
Increased Levels of Cell Death and Proliferation in Alveolar Wall Cells in Patients With Pulmonary Emphysema
Chest, February 1, 2004; 125(2): 626 - 632.
[Abstract] [Full Text] [PDF]

Home page
 Eur Respir JHome page
K. Aoshiba, T. Tsuji, and A. Nagai
Bleomycin induces cellular senescence in alveolar epithelial cells
Eur. Respir. J., September 1, 2003; 22(3): 436 - 443.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
H. Suzuki, K. Aoshiba, N. Yokohori, and A. Nagai
Epidermal Growth Factor Receptor Tyrosine Kinase Inhibition Augments a Murine Model of Pulmonary Fibrosis
Cancer Res., August 15, 2003; 63(16): 5054 - 5059.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
M. Kuroki, Y. Noguchi, M. Shimono, K. Tomono, T. Tashiro, Y. Obata, E. Nakayama, and S. Kohno
Repression of Bleomycin-Induced Pneumopathy by TNF
J. Immunol., January 1, 2003; 170(1): 567 - 574.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
F. Zuo, N. Kaminski, E. Eugui, J. Allard, Z. Yakhini, A. Ben-Dor, L. Lollini, D. Morris, Y. Kim, B. DeLustro, et al.
Gene expression analysis reveals matrilysin as a key regulator of pulmonary fibrosis in mice and humans
PNAS, April 30, 2002; 99(9): 6292 - 6297.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Pathol.Home page
C. Barazzone Argiroffo, Y. R. Donati, J. Boccard, A. F. Rochat, C. Vesin, C.-D. Kan, and P.-F. Piguet
CD40-CD40 Ligand Disruption Does Not Prevent Hyperoxia-Induced Injury
Am. J. Pathol., January 1, 2002; 160(1): 67 - 71.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
M. J. TOBIN
Tuberculosis, Lung Infections, and Interstitial Lung Disease in AJRCCM 2000
Am. J. Respir. Crit. Care Med., November 15, 2001; 164(10): 1774 - 1788.
[Full Text] [PDF]

Home page
 Am. J. Physiol. Lung Cell. Mol. Physiol.Home page
L. A. Ortiz, H. C. Champion, J. A. Lasky, F. Gambelli, E. Gozal, G. W. Hoyle, M. B. Beasley, A. L. Hyman, M. Friedman, and P. J. Kadowitz
Enalapril protects mice from pulmonary hypertension by inhibiting TNF-mediated activation of NF-kappa B and AP-1
Am J Physiol Lung Cell Mol Physiol, June 1, 2002; 282(6): L1209 - L1221.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Proc. Am. Thorac. Soc. Am. J. Respir. Cell Mol. Biol.
Copyright © 2000 American Thoracic Society 		  ATS Coding and Billing Quarterly